TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00554216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VI-0521
Description: 3.75 mg phentermine/23 mg topiramate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VI-0521
Description: 15 mg phentermine/92 mg topiramate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matched phentermine/topiramate
Description: Placebo matched phentermine/topiramate
Study: NCT00143715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phytonadione (Vitamin K1)
Description: 1.25 mg given orally
Study: NCT02340351

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Auricular acupuncture
Description: Auricular acupuncture according to the the NADA protocol includes the needling of five specific acupuncture points on both ears: point 51 (= Sympathetic point), point 55 (= Shen Men), point 95 (= Kidney point), point 97 (= Liver point) and point 101 (= Lung point). All points were acupunctured with fine sterile single use steel needles with the size of 0.25 x 20 millimetres. The needles were inserted about 2-3 millimetres, so that the needle point pierces the skin and is just positioned in the cartilage of the ear. They remained in position for 30 minutes.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Progressive muscle relaxation
Description: Progressive muscle relaxation was carried out by the method of Bernstein and Borkovec. All participants were asked to close eyes while sitting comfortably. Each group session included 16 main exercises of consciously tensing and relaxing specific groups of muscles.
Study: NCT01619969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celgosivir
Description: 100 mg capsules, 400 mg loading dose 200 mg bid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Capsules of identical appearance containing starch
Study: NCT04528966

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole-Body Vibration
Description: Whole-Body Vibration Treatment for 3 sessions in a week for 8 weeks. Each sessions takes 15 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physiotherapy
Description: conventional physiotherapy for 2 sessions in a week for 8 weeks. Each sessions takes 45 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Physiotherapy
Description: conventional physiotherapy for 2 sessions in a week for 8 weeks. Each sessions takes 45 minutes.
Study: NCT04704596

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: anesthesia ventilator machine
Description: dynamic lung compliance measurements will be used for detection of the optimum PEEP after alveolar recruitment

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lung ultrasound
Description: lung ultrasound views will be used for detection of the optimum PEEP after alveolar recruitment
Study: NCT03993652

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kids FIRST
Description: family- and school-based intervention to reduce unhealthy screen-time and snacking

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kids FIRST
Description: family- and school-based intervention to reduce unhealthy screen-time and snacking

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kids FIRST
Description: family- and school-based intervention to reduce unhealthy screen-time and snacking
Study: NCT01403597

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Refirme ST Applicator and Matrix RF Applicator
Description: 5 treatments with combination of devices every 4 weeks to the facial (or sub facial regions).
Study: NCT03319758

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: buccal bone augmentation
Description: Subjects in need of one implant replacing tooth to be removed in the maxilla within region 13-23 are included. At least 15 patients are recruited.
Study: NCT04535778

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COMPASS
Description: An 11 module, therapist-supported online CBT program.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard charity resources
Description: Resources provided by the charities involved, including supportive listening, online support groups, information resources and local community support groups.
Study: NCT02269267

Intervention type: DRUG
Group type: OTHER
Intervention: Imatinib (Stopping their TKI)
Description: Patients with CML on treatment with imatinib and are in confirmed deep molecular response will stop their TKI. Confirmed deep (\> 4 log reduction) molecular response (\>MR4) defined as p210 (bcr-abl) fusion protein (BCR-ABL) \< 0.01%, for at least two years. Concurrently, the study will assess a wide range of PROs before stopping TKIs and after discontinuation in conjunction with PCR testing, though at fewer time points, utilizing online and/or phone questionnaires.

Intervention type: DRUG
Group type: OTHER
Intervention: Dasatinib (Stopping their TKI)
Description: Patients with CML on treatment with dasatinib and are in confirmed deep molecular response will stop their TKI. Confirmed deep (\> 4 log reduction) molecular response (\>MR4) defined as p210 (bcr-abl) fusion protein (BCR-ABL) \< 0.01%, for at least two years. Concurrently, the study will assess a wide range of PROs before stopping TKIs and after discontinuation in conjunction with PCR testing, though at fewer time points, utilizing online and/or phone questionnaires.

Intervention type: DRUG
Group type: OTHER
Intervention: Nilotinib (Stopping their TKI)
Description: Patients with CML on treatment with nilotinib and are in confirmed deep molecular response will stop their TKI. Confirmed deep (\> 4 log reduction) molecular response (\>MR4) defined as p210 (bcr-abl) fusion protein (BCR-ABL) \< 0.01%, for at least two years. Concurrently, the study will assess a wide range of PROs before stopping TKIs and after discontinuation in conjunction with PCR testing, though at fewer time points, utilizing online and/or phone questionnaires.

Intervention type: DRUG
Group type: OTHER
Intervention: Bosutinib (Stopping their TKI)
Description: Patients with CML on treatment with bosutinib and are in confirmed deep molecular response will stop their TKI. Confirmed deep (\> 4 log reduction) molecular response (\>MR4) defined as p210 (bcr-abl) fusion protein (BCR-ABL) \< 0.01%, for at least two years. Concurrently, the study will assess a wide range of PROs before stopping TKIs and after discontinuation in conjunction with PCR testing, though at fewer time points, utilizing online and/or phone questionnaires.
Study: NCT01071798

Intervention type: DRUG
Intervention: Rituximab
Description: As prescribed by physician
Study: NCT00843284

Intervention type: DRUG
Intervention: Pregabalin
Description: Capsules, 150 - 600 mg/day, 2-3 times/day, 8 weeks
Study: NCT00482066

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abatacept (Orencia)
Description: 500mg for patients under 60kg 750mg for patients 60-100kg~1g for patients\>100kg given as i.v. infusion over 30 minutes at day 0, 14, 28 and then monthly for a further 11 months 914 infusions in total) placebo groups receive saline only I.v.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Abatacept (Orencia)
Description: 500mg for patients under 60kg 750mg for patients 60-100kg~1g for patients\>100kg given as i.v. infusion over 30 minutes at day 0, 14, 28 and then monthly for a further 11 months 914 infusions in total) placebo groups receive saline only I.v.
Study: NCT01732718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: 40 mg tablet by mouth daily for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin
Description: 40 mg tablet by mouth daily for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo tablet by mouth daily for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablet by mouth daily for 6 weeks
Study: NCT01474239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: 10 mg/kg every 2 weeks intravenously until disease progression or unacceptable toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fotemustine
Description: 75 mg/m2 intravenously on days 1, 8 and 15 followed by, after a 5 weeks interval, 100 mg/m2 on day 1 of a 3-weeks cycle. Until disease progression or unacceptable toxicity
Study: NCT04708314

Intervention type: DRUG
Group type: OTHER
Intervention: Golodirsen 50 MG/1 ML Intravenous Solution [VYONDYS 53]
Description: Vyondys 53
Study: NCT00143715

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Phytonadione (Vitamin K1)
Description: 1.25 mg given orally
Study: NCT02157675

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Polyherbal capsule

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Study: NCT01761292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Givinostat
Description: Givinostat, oral suspension 10 mg/mL or oral capsules 50 mg, administered orally under fed conditions at the dose of 25 mg BID, 37.5 mg BID, and 50 mg BID during Part 1 for two weeks, and 25 mg BID and 37.5 mg BID during Part 2 for 12 months. Givinostat, oral suspension 10 mg/mL, administered orally under fed conditions at the dose of 25 mg BID or 37.5 mg BID during Extension 1, and modified as per patient's weight during Extensions 2 and 3 (up to 52 months).
Study: NCT02951715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zinc gluconate
Description: 2 months of treatment with zinc gluconate (Zinga 78 mg, 10 mg elemental zinc), two tablets twice per day (40 mg per day)
Study: NCT03139812

Intervention type: DRUG
Group type: OTHER
Intervention: Daily irrigation
Description: Daily morning irrigation of the eye with sterile, borate-buffered, saline solution (Unisol 4) and gentle nudging of the lens to promote solution flow beneath the lens

Intervention type: DEVICE
Group type: OTHER
Intervention: 30-day SiH CW
Description: 30-day continuous wear of silicone hydrogel contact lenses

Intervention type: DEVICE
Group type: OTHER
Intervention: 30-day SiH CW
Description: 30-day continuous wear of silicone hydrogel contact lenses
Study: NCT00379652

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Medical Practice Improvement
Description: The details for the medical practice improvement intervention will be decided at a later date.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient Education and Support
Description: The details for the patient education and support intervention will be decided at a later date.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Combination Intervention to Include Medical Practice Improvement and Patient Education and Support
Description: The details for this combination intervention will be decided at a later date.
Study: NCT02853942

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous adipose stem cell therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mecobalamin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mecobalamin
Study: NCT03889314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20mg
Description: Statin Therapy

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03291366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCMSCC
Description: infusion of aUCMSC and conventional therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: conventional treatment
Description: conventional treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: conventional treatment
Description: conventional treatment
Study: NCT03542786

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: The probiotic i3.1 is a commercialized product. It will be supplied by the promoter and manufactured in ALIFARM S.A.~It contains:~* Lactobacillus plantarum CECT7484~* Lactobacillus plantarum CECT7485~* Pediococcus acidilactici CECT7483

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: The probiotic i3.1 is a commercialized product. It will be supplied by the promoter and manufactured in ALIFARM S.A.~It contains:~* Lactobacillus plantarum CECT7484~* Lactobacillus plantarum CECT7485~* Pediococcus acidilactici CECT7483

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotic
Description: ProSeed prebiotic is a non-commercialized product. It will be supplied by the promoter and manufactured in ALIFARM S.A.~It contains:~* Partially Hydrolyzed Guar Gum (PHGG)~* Inulin HPD~* Oat Beta-Glucans~* Pectin~* Inulin Low Protein Diet (LPD)~* Polydextrose~* Maltrodextrins

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: It is a non-commercialized product. It is composed of the same excipients as the probiotic and the prebiotic. It will be supplied by the promoter and manufactured in ALIFARM S.A.
Study: NCT01566773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT001 MDI
Description: Administered as two puffs BID for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT001 MDI
Description: Administered as two puffs BID for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT001 MDI
Description: Administered as two puffs BID for 14 days
Study: NCT02728492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quisinostat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quisinostat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quisinostat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quisinostat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quisinostat
Study: NCT02728492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quisinostat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quisinostat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study: NCT01566773

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium Bromide
Description: Taken as 1 capsule containing 18 µg of tiotropium via the Handihaler DPI

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PT001 Placebo MDI
Study: NCT02728492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Study: NCT03033537

Intervention type: DRUG
Intervention: Verapamil
Description: Local treatment of erectile dysfunction

Intervention type: DRUG
Intervention: Verapamil
Description: Local treatment of erectile dysfunction
Study: NCT00658476

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish Oil
Description: Omega-3 fatty acid supplements.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy
Description: Adolescents receive cognitive behavior therapy.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive Behavior Therapy
Description: Adolescents receive cognitive behavior therapy.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02728492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Study: NCT01350401

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Autologous genetically modified T cells, NY-ESO-1ᶜ²⁵⁹T
Description: Cytoreductive chemotherapy followed by infusion of NY-ESO-1ᶜ²⁵⁹T
Study: NCT01017380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: celecoxib 400 mg 1 cap before surgery
Study: NCT02541279

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy exercises guideline
Description: Exercises controlled by a physiotherapist.
Study: NCT01017380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoricoxib
Description: 120 mg 1 tab before surgery
Study: NCT02541279

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physiotherapy exercises guideline
Description: Exercises controlled by a physiotherapist.
Study: NCT00949832

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D + Calcium
Description: Vitamin D 50,000 IU orally once monthly for 6 months; Calcium carbonate (as powdered limestone) 500 mg orally twice daily for 6 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Calcium
Description: Calcium carbonate (as powdered limestone) 500 mg orally twice daily for 6 months; Vitamin B complex (used as placebo) 1 tablet monthly for 6 months

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D2
Description: 50,000 IU given orally once

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Vitamin D3 50,000 IU given orally once
Study: NCT02236520

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolactone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorthalidone

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Diet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01539681

Intervention type: DRUG
Intervention: Sorafenib (Nexavar, BAY43-9006)
Description: Subjects should be treated with sorafenib in compliance with the recommendations written in the local product information.However, the decision on the duration and dose of treatment is at the discretion of the prescribing physician.
Study: NCT00867373

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education Intervention
Description: The intervention is a short educational handout regarding BMI and the effect of parental weight status on children.
Study: NCT02154282

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ipod games
Description: Patients will be given ipod games for 4 weeks and tested in related and unrelated cognitive measures
Study: NCT00677274

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural labor analgesia
Description: Epidural analgesia initiated at the onset of regular uterine contraction

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural labor analgesia
Description: Epidural analgesia initiated at the cervix diameter 0.5cm

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural labor analgesia
Description: Epidural analgesia initiated at the cervix diameter 1.0cm

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural labor analgesia
Description: Epidural analgesia initiated at the cervix diameter 1.5cm
Study: NCT00539864

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FluBlok Influenza Vaccination
Description: 0.5mL dose for intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TIV (Fluzone) Influenza Vaccination
Description: 0.5mL dose for intramuscular injection
Study: NCT03439384

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home Telemonitoring
Description: Patients will monitor their weight, blood pressure, oxygen saturation and symptoms with sensors and a tablet computer provided to them. Patients are asked to do this everyday for 60-days. A monitoring nurse will be receiving the data electronically and reviewing on a daily basis.
Study: NCT02964013

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: vibostolimab
Description: Administered as an intravenous (IV) infusion on Day 1 of 21-day infusion Cycles 1-35
Study: NCT00677274

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural labor analgesia
Description: Epidural analgesia initiated at the cervix diameter 2.0cm

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural labor analgesia
Description: Epidural analgesia initiated at the cervix diameter 3.0cm

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural labor analgesia
Description: Epidural analgesia initiated at the cervix diameter 4.0cm

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural labor analgesia
Description: Epidural analgesia initiated at the cervix diameter 5.0cm
Study: NCT04411264

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: virtual reality
Description: Use of a virtual reality headset while caring for chronic wound dressings
Study: NCT02081534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1722
Description: AZD1722, oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1722
Description: AZD1722, oral tablet
Study: NCT02964013

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: vibostolimab
Description: Administered as an intravenous (IV) infusion on Day 1 of 21-day infusion Cycles 1-35

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: vibostolimab
Description: Administered as an intravenous (IV) infusion on Day 1 of 21-day infusion Cycles 1-35

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: vibostolimab
Description: Administered as an intravenous (IV) infusion on Day 1 of 21-day infusion Cycles 1-35

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: vibostolimab
Description: Administered as an intravenous (IV) infusion on Day 1 of 21-day infusion Cycles 1-35
Study: NCT02427997

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treadmill training with Virtual Reality
Description: VR is defined in general as a high-end-computer interface that involves real time simulation and interactions through multiple sensorial channels. The VR system to be used requires subjects to negotiate virtual obstacles while walking on a treadmill, in a safe environment. This dual task activity has large cognitive components such as information processing, planning, and attention while allowing for training in a more stimulating and enriching environment that includes both cognitive and motor components.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill training
Description: The participants will walk on the treadmill, their gait speed over-ground will be measured at the beginning of each week of training. Progression will include increasing the duration of each of the walking bouts and increasing walking speed.
Study: NCT01014351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel, 175mg/m2 by IV infusion over 1-3 hours on day 1 of every 21 day cycle
Study: NCT01014351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin, AUC 6 given by IV infusion over 20-30 minutes on day 1 of every 21 day cycle